| Literature DB >> 24598012 |
Jiayang Qin1, Xiuwen Wang2, Jian Kong3, Cuiqing Ma4, Ping Xu5.
Abstract
In this study, a food-grade cell surface display host/vector system for Lactobacillus casei was constructed. The food-grade host L. casei Q-5 was a lactose-deficient derivative of L. casei ATCC 334 obtained by plasmid elimination. The food-grade cell surface display vector was constructed based on safe DNA elements from lactic acid bacteria containing the following: pSH71 replicon from Lactococcus lactis, lactose metabolism genes from L. casei ATCC 334 as complementation markers, and surface layer protein gene from Lactobacillus acidophilus ATCC 4356 for cell surface display. The feasibility of the new host/vector system was verified by the expression of green fluorescent protein (GFP) on L. casei. Laser scanning confocal microscopy and immunofluorescence analysis using anti-GFP antibody confirmed that GFP was anchored on the surface of the recombinant cells. The stability of recombinant L. casei cells in artificial gastrointestinal conditions was verified, which is beneficial for oral vaccination applications. These results indicate that the food-grade host/vector system can be an excellent antigen delivery vehicle in oral vaccine construction.Entities:
Keywords: Food-grade; Lactobacillus casei; Plasmid elimination; Surface display
Mesh:
Substances:
Year: 2014 PMID: 24598012 PMCID: PMC7126567 DOI: 10.1016/j.micres.2014.02.001
Source DB: PubMed Journal: Microbiol Res ISSN: 0944-5013 Impact factor: 5.415
Strains, plasmids, and primers used in this study.
| Strain, plasmid or primer | Characteristics or sequence | Source or reference |
|---|---|---|
| Transformation host | Novagen | |
| Wild strain isolated from Emmental cheese, Lac+ | ATCC | |
| Plasmid-cured derivative of | This study | |
| Wide type strain, isolated from human, the donor of the signal peptide, promoter, and | ATCC | |
| pBAD-GFPuv | Apr, the donor of the | |
| pNZ2102 | Cmr, pSH71-derived lactococcal vector harboring the | |
| pNZ2102-lacEGF | Cmr, P | This study |
| pQJ-gfp | Cms, P | This study |
| yz1 | 5′-TTTCCTGCGGTGTCG-3′ | This study |
| yz2 | 5′-TTCGCCTTTGTTCTACTG-3′ | This study |
| yz3 | 5′-TGCCATCTGGGAGTTT-3′ | This study |
| yz4 | 5′-GGCTTATGCGAAGTTTT-3′ | This study |
| L9 | 5′-GCG | This study |
| L8 | 5′-GCG | This study |
| P1 | 5′-TGC | This study |
| P2 | 5′-CCTTTACTCATTCTAAAGTTTGCAACCTTA-3′ | This study |
| P3 | 5′-CAAACTTTAGAATGAGTAAAGGAGAAGAACTT-3′ | This study |
| P4 | 5′-CGC | This study |
| C1 | 5′-GATCTCA | This study |
| C2 | 5′-GCG | This study |
The underlined letters indicate the introduction of restriction sites.
Fig. 1Screening for plasmid 1-eliminated L. casei strains by PCR. Lane M, marker DNAs; Lane 0, L. casei ATCC 334; Lane 5, strain 5; Lane 9, strain 5; Lane A, strain A; Lane F, strain F.
Fig. 2Cell growth (A), lactose consumption (B) and l-lactic acid production (C) of strain 5 and L. casei ATCC 334 in MRS medium with lactose instead of glucose as the carbon source.
Fig. 3Detection of plasmid recovery of strain 5 after 20 passages. Lane M, marker DNAs; Lane 1, PCR using primers yz1, yz2 and L. casei ATCC 334; Lane 2, PCR using primers yz1, yz2 and strain 5; Lane 3, PCR using primers yz3, yz4 and L. casei ATCC 334; Lane 4, PCR using primers yz3, yz4 and strain 5.
Fig. 4Construction of the food-grade cell surface display vector.
Fig. 5Detection of fluorescence by laser scanning confocal microscopy (40× magnification objective). (A) Fluorescence detection of L. casei Q-5 cells harboring pQJ-gfp; (B) fluorescence detection of L. casei Q-5 cells harboring pNZ2102-lacEGF; (C) immunofluorescence detection of L. casei Q-5 cells harboring pQJ-gfp treated with anti-GFP antibody and Cy3-conjugated secondary antibody; (D) immunofluorescence detection of L. casei Q-5 cells harboring pNZ2102-lacEGF treated with anti-GFP antibody and Cy3-conjugated secondary antibody.
Survival of L. casei Q-5 harboring pQJ-gfp in artificial gastrointestinal juice.
| Strain | Treatment | Viability (CFU/mL) | Survival (%) |
|---|---|---|---|
| Before treatment | (2.48 ± 0.20) × 108 | ||
| Treated with AGJ | (7.30 ± 0.66) × 105 | 0.29 ± 0.05 | |
| Treated with AIJ | (1.13 ± 0.32) × 106 | 0.46 ± 0.09 | |
| Before treatment | (2.42 ± 0.03) × 108 | ||
| Treated with AGJ | (1.93 ± 0.25) × 108 | 79.72 ± 10.88 | |
| Treated with AIJ | (3.35 ± 0.76) × 108 | 138.48 ± 32.51 | |
Each value is the mean ± standard deviation of three trials.
Incubation in the artificial gastric juice (AGJ), pH 2.0 at 37 °C for 2 h.
Extended incubation in the artificial intestinal juice (AIJ), pH 6.8 at 37 °C for 5 h.
Genetically engineered live vaccines developed by L. casei.
| Host | Vector | Selection marker | Protein expressed | Protein location | References |
|---|---|---|---|---|---|
| pPG1 and pPG2 | Chloramphenicol | Porcine epidemic diarrhea virus S1 region and nucleocapsid protein | Cell surface and extracellular | ||
| pLA | Chloramphenicol | K99, K88 fimbrial protein | Cell surface | ||
| pPG612.1 | Chloramphenicol | CSFV-specific CTL epitope and PPV VP2 protein | Extracellular | ||
| pLP401 | Erythromycin | Flagellar antigen | Cell surface | ||
| pPG611.1 | Chloramphenicol | Porcine parvovirus VP2 protein | Cell surface | ||
| pIAlac | Erythromycin | Human papillomavirus type 16 L1 protein | Intracellular | ||
| pHAT | Erythromycin | Severe acute respiratory syndrome coronavirus spike protein | Cell surface | ||
| pLP500 | Erythromycin | Transmissible gastroenteritis coronavirus spike glycoprotein | Extracellular |